<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:02:35Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8410141" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8410141</identifier>
        <datestamp>2021-09-02</datestamp>
        <setSpec>jncicanspec</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JNCI Cancer Spectr</journal-id>
              <journal-id journal-id-type="iso-abbrev">JNCI Cancer Spectr</journal-id>
              <journal-id journal-id-type="publisher-id">jncics</journal-id>
              <journal-title-group>
                <journal-title>JNCI Cancer Spectrum</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2515-5091</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8410141</article-id>
              <article-id pub-id-type="pmcid">PMC8410141</article-id>
              <article-id pub-id-type="pmc-uid">8410141</article-id>
              <article-id pub-id-type="pmid">34485815</article-id>
              <article-id pub-id-type="doi">10.1093/jncics/pkab070</article-id>
              <article-id pub-id-type="publisher-id">pkab070</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00010</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2907-1000</contrib-id>
                  <name>
                    <surname>Sinicrope</surname>
                    <given-names>Frank A</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="pkab070-aff1" ref-type="aff">1</xref>
                  <xref rid="pkab070-cor1" ref-type="corresp"/>
                  <!--sinicrope.frank@mayo.edu-->
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4640-8832</contrib-id>
                  <name>
                    <surname>Shi</surname>
                    <given-names>Qian</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="pkab070-aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Smyrk</surname>
                    <given-names>Thomas C</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="pkab070-aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0308-8223</contrib-id>
                  <name>
                    <surname>Goldberg</surname>
                    <given-names>Richard M</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="pkab070-aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cohen</surname>
                    <given-names>Steven J</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="pkab070-aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gill</surname>
                    <given-names>Sharlene</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="pkab070-aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kahlenberg</surname>
                    <given-names>Morton S</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="pkab070-aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7763-9732</contrib-id>
                  <name>
                    <surname>Nair</surname>
                    <given-names>Suresh</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="pkab070-aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shield</surname>
                    <given-names>Anthony F</given-names>
                  </name>
                  <degrees>MDS</degrees>
                  <xref rid="pkab070-aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jahagirdar</surname>
                    <given-names>Balkrishna N</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="pkab070-aff9" ref-type="aff">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jacobson</surname>
                    <given-names>Sawyer B</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref rid="pkab070-aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Foster</surname>
                    <given-names>Nathan R</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="pkab070-aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3047-0604</contrib-id>
                  <name>
                    <surname>Pollak</surname>
                    <given-names>Michael N</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="pkab070-aff10" ref-type="aff">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Alberts</surname>
                    <given-names>Steven R</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="pkab070-aff1" ref-type="aff">1</xref>
                </contrib>
              </contrib-group>
              <aff id="pkab070-aff1"><label>1</label><institution>Division of Oncology and Mayo Clinic Comprehensive Cancer Center</institution>, Rochester, MN, <country country="US">USA</country></aff>
              <aff id="pkab070-aff2"><label>2</label><institution>Alliance Statistics and Data Center, Mayo Clinic</institution>, Rochester, MN, <country country="US">USA</country></aff>
              <aff id="pkab070-aff3"><label>3</label><institution>West Virginia University Cancer Institute</institution>, Morgantown, WV, <country country="US">USA</country></aff>
              <aff id="pkab070-aff4"><label>4</label><institution>Fox Chase Cancer Center</institution>, Philadelphia, PA, <country country="US">USA</country></aff>
              <aff id="pkab070-aff5"><label>5</label><institution>British Columbia Cancer Agency, Vancouver Cancer Centre</institution>, Vancouver, BC, <country country="CA">Canada</country></aff>
              <aff id="pkab070-aff6"><label>6</label><institution>Surgical Oncology Associates of South Texas,</institution> San Antonio, TX, <country country="US">USA</country></aff>
              <aff id="pkab070-aff7"><label>7</label><institution>Lehigh Valley Hospital</institution>, Allentown, PA, <country country="US">USA</country></aff>
              <aff id="pkab070-aff8"><label>8</label><institution>Wayne State University, Karmanos Cancer Institute</institution>, Detroit, MI, <country country="US">USA</country></aff>
              <aff id="pkab070-aff9"><label>9</label><institution>Metro Minnesota Community Oncology Research Consortium</institution>, Saint Paul, MN, <country country="US">USA</country></aff>
              <aff id="pkab070-aff10"><label>10</label><institution>McGill University</institution>, Montreal, QC, <country country="CA">Canada</country></aff>
              <author-notes>
                <corresp id="pkab070-cor1"><bold>Correspondence to:</bold> Frank A. Sinicrope, MD, Mayo Clinic and Mayo Comprehensive Cancer Center, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA (e-mail: <email>sinicrope.frank@mayo.edu</email>).</corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>10</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2021-07-23">
                <day>23</day>
                <month>7</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>23</day>
                <month>7</month>
                <year>2021</year>
              </pub-date>
              <volume>5</volume>
              <issue>5</issue>
              <elocation-id>pkab070</elocation-id>
              <history>
                <date date-type="received">
                  <day>21</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-recd">
                  <day>03</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>21</day>
                  <month>7</month>
                  <year>2021</year>
                </date>
                <date date-type="corrected-typeset">
                  <day>31</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2021. Published by Oxford University Press.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="pkab070.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="s1">
                  <title>Background</title>
                  <p>Adipocyte-derived adiponectin may play a role in the host inflammatory response to cancer. We examined the association of plasma adiponectin with the density of tumor-infiltrating lymphocytes (TILs) in colon cancers and with vitamin D, clinicopathological features, and patient survival.</p>
                </sec>
                <sec id="s2">
                  <title>Methods</title>
                  <p>Plasma adiponectin and 25-hydroxyvitamin D [25(OH)D] were analyzed by radioimmunoassay in 600 patients with stage III colon cancer who received FOLFOX-based adjuvant chemotherapy (NCCTG N0147 [Alliance]). TIL densities were determined in histopathological sections. Associations with disease-free survival (DFS), time to recurrence, and overall survival were evaluated by multivariable Cox regression adjusting for potential confounders (ie, body mass index, race, TILs, and N stage). All statistical tests were 2-sided.</p>
                </sec>
                <sec id="s3">
                  <title>Results</title>
                  <p>We found a statistically significant reduction in adiponectin, but not 25(OH)D, levels in tumors with high vs low TIL densities (median<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>6845 vs 8984 ng/mL; <italic toggle="yes">P</italic> = .04). A statistically significant reduction in adiponectin was also observed in obese (body mass index &gt;30 kg/m<sup>2</sup>) vs nonobese patients (median<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>6608 vs 12 351 ng/mL; <italic toggle="yes">P</italic> &lt; .001), in men vs women (median<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>8185 vs 11 567 ng/mL; <italic toggle="yes">P</italic> &lt; .001), in Blacks vs Whites or Asians (median<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>6412 vs 8847 vs 7858 ng/mL; <italic toggle="yes">P</italic> &lt; .03), and in those with fewer lymph node metastases (N1 vs N2: median<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>7768 vs 9253 ng/mL; <italic toggle="yes">P</italic> = .01). Insufficiency of 25(OH)D (&lt;30 ng/mL) was detected in 291 (48.5%) patients. In multivariable analyses, neither adiponectin nor 25(OH)D were associated with a statistically significant difference in DFS, overall survival , or time to recurrence in models adjusted for potential confounders. We found a statistically significant association of TILs with prognosis, yet no such interaction was observed for the association of adiponectin with TILs for DFS.</p>
                </sec>
                <sec id="s4">
                  <title>Conclusions</title>
                  <p>Lower circulating adiponectin levels were associated with a statistically significant increase in TIL densities in colon cancers, indicating an enhanced antitumor immune response. In contrast to TILs, neither adiponectin nor 25(OH)D was independently prognostic.</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Cancer Institute (NCI) of the National Institutes of Health (NIH)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>U10CA180821</award-id>
                  <award-id>U10CA180882</award-id>
                  <award-id>U10CA180863</award-id>
                  <award-id>CCSRI 021039 (CCTG)</award-id>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="9"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p>Colorectal cancer (CRC) is the third most common cancer and is second only to lung cancer as a cause of cancer-related mortality in the United States (<xref rid="pkab070-B1" ref-type="bibr">1</xref>). Obesity is an established risk factor in this malignancy, and it is postulated that adiponectin may mediate the biological link between obesity and CRC (<xref rid="pkab070-B2" ref-type="bibr">2</xref>). Although the mechanism for this potential link is unknown, adipocyte-derived adiponectin may play a role in immune regulation and in the host inflammatory response to cancer (<xref rid="pkab070-B3" ref-type="bibr">3</xref>,<xref rid="pkab070-B4" ref-type="bibr">4</xref>). Adiponectin, the most abundant hormone secreted by adipose tissue, senses metabolic stress and modulates metabolic adaption by targeting the innate immune system under physiological and pathological conditions (<xref rid="pkab070-B5" ref-type="bibr">5</xref>). Epidemiological studies suggest an inverse association between plasma adiponectin levels and risk of developing CRC (<xref rid="pkab070-B6" ref-type="bibr">6</xref>,<xref rid="pkab070-B7" ref-type="bibr">7</xref>). This inverse relationship was observed among men, but not women, in the Nurses’ Health Study and Health Professionals Follow-up Study (<xref rid="pkab070-B6" ref-type="bibr">6</xref>). In a meta-analysis of patients with established CRC, a statistically significant decrease in adiponectin levels was observed compared with non CRC controls (<xref rid="pkab070-B8" ref-type="bibr">8</xref>). Limited data suggest an association between prediagnostic plasma adiponectin and risk of CRC-specific and overall mortality (<xref rid="pkab070-B9" ref-type="bibr">9</xref>). However, the only prospective study of adiponectin measured at the time of diagnosis of CRC was not prognostic (<xref rid="pkab070-B10" ref-type="bibr">10</xref>), and postdiagnosis data are lacking.</p>
            <p>Plasma adiponectin was found to be associated with vitamin D levels in non-CRC patients (<xref rid="pkab070-B11" ref-type="bibr">11</xref>). Vitamin D insufficiency (&lt;30 ng/mL) is relatively common in healthy individuals and in CRC populations (<xref rid="pkab070-B12" ref-type="bibr">12</xref>). Serum 25-hydroxyvitamin D [25(OH)D] was inversely associated with CRC risk (<xref rid="pkab070-B13" ref-type="bibr">13</xref>), and some studies suggest that 25(OH)D insufficiency in patients with established CRC may be associated with worse clinical outcome (<xref rid="pkab070-B14" ref-type="bibr">14-16</xref>). Individuals deficient in vitamin D had statistically significantly higher levels of the serum inflammatory biomarkers interleukin-6 (IL-6) and C-reactive protein (<xref rid="pkab070-B17" ref-type="bibr">17</xref>). Interestingly, a prior study found that a high 25(OH)D level was associated with a lower risk of developing CRC with an intense immune reaction (<xref rid="pkab070-B18" ref-type="bibr">18</xref>), suggesting that vitamin D may influence the tumor-host interaction. In a study of the 25(OH)D score measured post-CRC diagnosis, its association with CRC-specific mortality differed by the extent of peritumoral lymphocytic reaction (<xref rid="pkab070-B19" ref-type="bibr">19</xref>).</p>
            <p>To date, adiponectin has not been analyzed in relationship to the tumor immune microenvironment. We sought to test the hypothesis that adiponectin may play a role in the host inflammatory response to colon cancer, indicated by tumor-infiltrating lymphocytes (TILs). In patients with CRC, studies indicate that TILs can independently predict recurrence and survival (<xref rid="pkab070-B20" ref-type="bibr">20-22</xref>). However, only limited data exist for adiponectin or vitamin D in patients with established CRC, and their impact on survival is largely unknown. We determined the association of postsurgical plasma adiponectin levels with TIL densities, 25(OH)D, clinicopathological features, and clinical outcome in patients with stage III colon cancers from a phase III adjuvant trial of FOLFOX-based chemotherapy (NCCTG N0147 [Alliance]) (<xref rid="pkab070-B23" ref-type="bibr">23</xref>).</p>
            <sec sec-type="methods">
              <title>Methods</title>
              <sec>
                <title>Study Population</title>
                <p>Among 2686 patients with resected stage III colon cancer who had been randomly assigned to adjuvant FOLFOX alone or combined with cetuximab, we randomly selected 600 patients (300 per arm) for analysis of adiponectin and 25(OH)D (NCCTG N0147; ClinicalTrials.gov Identifier: NCT00079274). Right-sided tumors were defined as located proximal to the splenic flexure. N1 tumors had 1-3 metastatic regional lymph nodes; N2 tumors had at least 4 nodes. All patients provided written informed consent at the time of clinical trial enrollment. All data analyses shown here were approved by Mayo Clinic Institution Review Board.</p>
              </sec>
              <sec>
                <title>Adiponectin and Vitamin D Assays</title>
                <p>Plasma adiponectin and 25(OH)D were analyzed in processed and stored blood obtained at adjuvant study registration. Biomarker concentrations were measured by radioimmunoassay (laboratory of M. Pollak, McGill University, Montreal, QC, Canada) as previously described (<xref rid="pkab070-B24" ref-type="bibr">24</xref>). Circulating levels of total and high molecular weight adiponectin were measured in duplicate using standard enzyme-linked immunosorbent assay methods. Because total and high molecular weight adiponectin levels were almost perfectly correlated (Spearman <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>.99), we report total adiponectin. 25(OH)D was extracted from serum or plasma with acetonitrile, and samples were then assayed using an equilibrium radioimmunoassay procedure using an antibody specific for 25(OH)D (<xref rid="pkab070-B24" ref-type="bibr">24</xref>). Blinded quality control (QC) samples were included with test samples, and pooled QC specimens were added to each of the batches. For both assays, masked QC samples were interspersed among case samples. All laboratory personnel were blinded to patient outcomes. The mean coefficient of variation of the assay was 8%.</p>
              </sec>
              <sec>
                <title>Histologic Examination of TILs</title>
                <p>A representative hematoxylin and eosin-stained tumor section from each patient was scanned at low power to identify areas with the most intraepithelial TILs. Once identified, 5 consecutive 40X fields were counted, and mean TILs per high power field (HPF) were calculated by dividing the total number of TILs by 5. All cases were scored independently by 2 gastrointestinal pathologists blinded to clinical and molecular data (<xref rid="pkab070-B25" ref-type="bibr">25</xref>). Cutoffs for TIL densities were previously determined in N0147 tumors based on their association with patient (disease-free survival [DFS]) and categorized as low (≤3 per HPF) vs high (&gt;3 per HPF) TILs (<xref rid="pkab070-B25" ref-type="bibr">25</xref>).</p>
              </sec>
              <sec>
                <title>DNA Mismatch Repair (MMR) Status and <italic toggle="yes">KRAS</italic>/<italic toggle="yes">BRAF</italic> Mutation Analysis</title>
                <p>Prospectively collected tumor tissues were analyzed for MMR status by analysis of MLH1, MSH2, and MSH6 proteins using immunohistochemistry. Tumors with deficient MMR were defined as having absent expression of 1 or more MMR protein. Testing for a <italic toggle="yes">BRAF</italic> (c.1799T&gt;A V600E) mutation in exon 15 and <italic toggle="yes">KRAS</italic> mutations in codons 12 and 13 of exon 2 was previously described (<xref rid="pkab070-B26" ref-type="bibr">26</xref>).</p>
              </sec>
              <sec>
                <title>Statistical Analysis</title>
                <p>Adiponectin and 25(OH)D were analyzed as continuous variables in the primary analysis. As binary variables, adiponectin was dichotomized at the median, and 25(OH)D was dichotomized at 30 ng/ml with lower levels regarded as insufficiency (<xref rid="pkab070-B12" ref-type="bibr">12</xref>). The association of adiponectin with TILs was prespecified as the primary analysis and was analyzed by the Kruskal Wallis test. Associations between adiponectin and 25(OH)D and with clinicopathological features were assessed by Fisher exact, Pearson χ<sup>2</sup>, <italic toggle="yes">t</italic> test, and Kruskal-Wallis tests as appropriate. The association between adiponectin and clinical outcomes were as follows: DFS, time from randomization to recurrence or death from any cause; overall survival (OS), time from randomization to death from all causes; and time to recurrence (TTR) as time from randomization to recurrence. Distributions of DFS, OS, and TTR were estimated by the Kaplan-Meier method. Biomarkers were analyzed in relationship to clinical outcome as continuous variables using a relative risk model with cubic splines and as binary variables in multivariable Cox regression. Multivariable models included variables that were considered to be potential confounders. Interaction tests were performed. A 2-sided <italic toggle="yes">P</italic> value of less than  .05 was considered statistically significant and was not adjusted for multiple comparisons. SAS software version 9.4 and R version 3.6.2 were used (SAS Institute, Cary, NC).</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>Results</title>
              <sec>
                <title>Association of Plasma Adiponectin and 25(OH)D With Patient Characteristics and TILs</title>
                <p>The frequency distribution and median levels of plasma adiponectin and 25(OH)D are shown in <xref rid="pkab070-F1" ref-type="fig">Figure 1</xref>. We found a statistically significant decrease in the level of adiponectin in patients whose tumors had high vs low TIL densities (median<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>6845 vs 8984 ng/mL; <italic toggle="yes">P</italic> = .04) (<xref rid="pkab070-T1" ref-type="table">Table 1</xref>). Furthermore, a statistically significant and inverse association between adiponectin level and body mass index (BMI) category was observed whereby obese patients had a lower median adiponectin level (median<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>6608 ng/mL) than did those of normal weight (median<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>10 693 ng/mL) or underweight (median<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>18 010 ng/mL; <italic toggle="yes">P</italic> &lt; .001). A statistically significant decrease in adiponectin was observed in men vs women (median<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>8185 vs 11 567 ng/mL; <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>.001), in those aged 65 years or younger (median<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>7663 vs 9279 ng/mL; <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>.007), and in Blacks vs Whites or Asians (median<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>6412 vs 8847 vs 7858 ng/mL; <italic toggle="yes">P</italic> &lt; .03) (<xref rid="pkab070-T1" ref-type="table">Table 1</xref>). Findings by race were not explained by differences in BMI, which was similar by race. Adiponectin levels differed by N stage in that a lower level was associated with fewer regional lymph node metastases (N1 vs N2: median<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>7768 vs 9253 ng/mL; <italic toggle="yes">P</italic> = .01). Adiponectin was not associated with a statistically significant correlation with 25(OH)D (Spearman <italic toggle="yes">r </italic>=<italic toggle="yes"> </italic>−.0038; <italic toggle="yes">P</italic> = .93) or with T stage, DNA MMR, or the mutational status of <italic toggle="yes">KRAS</italic> or <italic toggle="yes">BRAF</italic> genes.</p>
                <fig position="float" id="pkab070-F1">
                  <label>Figure 1.</label>
                  <caption>
                    <p>Frequency distributions of postsurgical plasma adiponectin (<bold>left</bold>) and 25-hydroxyvitamin D (<bold>right</bold>) in 600 patients with surgically resected stage III colon cancers treated with adjuvant FOLFOX-based chemotherapy.</p>
                  </caption>
                  <graphic xlink:href="pkab070f1" position="float"/>
                </fig>
                <table-wrap position="float" id="pkab070-T1">
                  <label>Table 1.</label>
                  <caption>
                    <p>Association between plasma adiponectin level and clinicopathological variables</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="2" colspan="1">Variable</th>
                        <th rowspan="2" colspan="1">No.</th>
                        <th colspan="3" rowspan="1">Plasma adiponectin level, ng/mL<hr/></th>
                        <th rowspan="2" colspan="1">
                          <italic toggle="yes">P</italic>
                          <xref rid="tblfn1" ref-type="table-fn">
                            <sup>a</sup>
                          </xref>
                        </th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1">Mean (SD)</th>
                        <th rowspan="1" colspan="1">Median</th>
                        <th rowspan="1" colspan="1">Q 1, Q3</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Age, y</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.007</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> ≤65</td>
                        <td rowspan="1" colspan="1">420</td>
                        <td rowspan="1" colspan="1">9372.2 (5877.4)</td>
                        <td rowspan="1" colspan="1">7663.0</td>
                        <td rowspan="1" colspan="1">5106.0, 12 419.5</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> &gt;65</td>
                        <td rowspan="1" colspan="1">180</td>
                        <td rowspan="1" colspan="1">10 751.7 (6382.7)</td>
                        <td rowspan="1" colspan="1">9279.0</td>
                        <td rowspan="1" colspan="1">6268.8, 13 581.8</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Race</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.002</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Asian</td>
                        <td rowspan="1" colspan="1">28</td>
                        <td rowspan="1" colspan="1">9503.2 (5247.7)</td>
                        <td rowspan="1" colspan="1">7858.0</td>
                        <td rowspan="1" colspan="1">5110.2, 13 653.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Black</td>
                        <td rowspan="1" colspan="1">53</td>
                        <td rowspan="1" colspan="1">7245.5 (4791.3)</td>
                        <td rowspan="1" colspan="1">6412.0</td>
                        <td rowspan="1" colspan="1">4086.0, 8988.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> White</td>
                        <td rowspan="1" colspan="1">502</td>
                        <td rowspan="1" colspan="1">10 065.3 (6115.2)</td>
                        <td rowspan="1" colspan="1">8847.0</td>
                        <td rowspan="1" colspan="1">5472.5, 12 842.8</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Sex</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Female</td>
                        <td rowspan="1" colspan="1">284</td>
                        <td rowspan="1" colspan="1">11 567.9 (6528.8)</td>
                        <td rowspan="1" colspan="1">10 439.0</td>
                        <td rowspan="1" colspan="1">6420.2, 14 978.5</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Male</td>
                        <td rowspan="1" colspan="1">316</td>
                        <td rowspan="1" colspan="1">8184.7 (5111.8)</td>
                        <td rowspan="1" colspan="1">6816.5</td>
                        <td rowspan="1" colspan="1">4466.2, 10 694.8</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">BMI</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Underweight</td>
                        <td rowspan="1" colspan="1">10</td>
                        <td rowspan="1" colspan="1">16944.1 (9775.4)</td>
                        <td rowspan="1" colspan="1">18009.5</td>
                        <td rowspan="1" colspan="1">8890.0, 25 879.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Normal</td>
                        <td rowspan="1" colspan="1">159</td>
                        <td rowspan="1" colspan="1">12 218.2 (6908.1)</td>
                        <td rowspan="1" colspan="1">10693.0</td>
                        <td rowspan="1" colspan="1">6906.0, 15 800.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overweight</td>
                        <td rowspan="1" colspan="1">210</td>
                        <td rowspan="1" colspan="1">9454.6 (5508.4)</td>
                        <td rowspan="1" colspan="1">8350.0</td>
                        <td rowspan="1" colspan="1">52 38.5, 12 040.8</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Obese</td>
                        <td rowspan="1" colspan="1">218</td>
                        <td rowspan="1" colspan="1">7938.8 (4759.6)</td>
                        <td rowspan="1" colspan="1">6608.0</td>
                        <td rowspan="1" colspan="1">45 96.0, 10 348.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">T stage</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.48</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> T1 or T2</td>
                        <td rowspan="1" colspan="1">96</td>
                        <td rowspan="1" colspan="1">9348.5 (6397.1)</td>
                        <td rowspan="1" colspan="1">6961.0</td>
                        <td rowspan="1" colspan="1">5084.0, 12 162.8</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> T3</td>
                        <td rowspan="1" colspan="1">441</td>
                        <td rowspan="1" colspan="1">9896.8 (6013.4)</td>
                        <td rowspan="1" colspan="1">8580.0</td>
                        <td rowspan="1" colspan="1">5328.0, 12 729.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> T4</td>
                        <td rowspan="1" colspan="1">63</td>
                        <td rowspan="1" colspan="1">9677.5 (5933.8)</td>
                        <td rowspan="1" colspan="1">8741.0</td>
                        <td rowspan="1" colspan="1">5411.5, 12 695.5</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">N stage</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.01</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> N1</td>
                        <td rowspan="1" colspan="1">365</td>
                        <td rowspan="1" colspan="1">9372.3 (6008.2)</td>
                        <td rowspan="1" colspan="1">7768.0</td>
                        <td rowspan="1" colspan="1">4959.0, 12 069.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> N2</td>
                        <td rowspan="1" colspan="1">235</td>
                        <td rowspan="1" colspan="1">10 428.7 (6099.8)</td>
                        <td rowspan="1" colspan="1">9253.0</td>
                        <td rowspan="1" colspan="1">5733.0, 13 262.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Performance status</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.93</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 0</td>
                        <td rowspan="1" colspan="1">453</td>
                        <td rowspan="1" colspan="1">9791.9 (6015.2)</td>
                        <td rowspan="1" colspan="1">8435.0</td>
                        <td rowspan="1" colspan="1">5308.0, 12 729.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 1</td>
                        <td rowspan="1" colspan="1">141</td>
                        <td rowspan="1" colspan="1">9706.5 (6178.2)</td>
                        <td rowspan="1" colspan="1">8145.0</td>
                        <td rowspan="1" colspan="1">5215.0, 11 977.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 2</td>
                        <td rowspan="1" colspan="1">6</td>
                        <td rowspan="1" colspan="1">11 212.0 (7671.0)</td>
                        <td rowspan="1" colspan="1">10 068.0</td>
                        <td rowspan="1" colspan="1">4993.0, 17 817.5</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Tumor location</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.74</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Left</td>
                        <td rowspan="1" colspan="1">286</td>
                        <td rowspan="1" colspan="1">9822.6 (5996.2)</td>
                        <td rowspan="1" colspan="1">8390.0</td>
                        <td rowspan="1" colspan="1">5331.2, 13 020.8</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Right</td>
                        <td rowspan="1" colspan="1">303</td>
                        <td rowspan="1" colspan="1">9721.2 (5957.8)</td>
                        <td rowspan="1" colspan="1">8354.0</td>
                        <td rowspan="1" colspan="1">5250.0, 12 285.5</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">TILs</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.04</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Low (≤3)</td>
                        <td rowspan="1" colspan="1">248</td>
                        <td rowspan="1" colspan="1">10 163.4 (5881.1)</td>
                        <td rowspan="1" colspan="1">8983.5</td>
                        <td rowspan="1" colspan="1">5575.5, 13 467.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> High (&gt;3)</td>
                        <td rowspan="1" colspan="1">100</td>
                        <td rowspan="1" colspan="1">9294.3 (6612.9)</td>
                        <td rowspan="1" colspan="1">6844.5</td>
                        <td rowspan="1" colspan="1">4945.5, 11 389.8</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <italic toggle="yes">BRAF</italic>
                        </td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.85</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Mutant</td>
                        <td rowspan="1" colspan="1">198</td>
                        <td rowspan="1" colspan="1">9548.7 (5729.9)</td>
                        <td rowspan="1" colspan="1">8147.0</td>
                        <td rowspan="1" colspan="1">5501.8, 12 046.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Wild type</td>
                        <td rowspan="1" colspan="1">357</td>
                        <td rowspan="1" colspan="1">9829.8 (6070.0)</td>
                        <td rowspan="1" colspan="1">8434.0</td>
                        <td rowspan="1" colspan="1">5215.0, 12 729.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <italic toggle="yes">KRAS</italic>
                        </td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.61</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Mutant</td>
                        <td rowspan="1" colspan="1">73</td>
                        <td rowspan="1" colspan="1">10 287.8 (6416.9)</td>
                        <td rowspan="1" colspan="1">8492.0</td>
                        <td rowspan="1" colspan="1">5443.0, 12 729.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Wild type</td>
                        <td rowspan="1" colspan="1">482</td>
                        <td rowspan="1" colspan="1">9645.0 (5875.3)</td>
                        <td rowspan="1" colspan="1">8350.0</td>
                        <td rowspan="1" colspan="1">5278.5, 12 552.5</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">MMR</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.96</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> dMMR</td>
                        <td rowspan="1" colspan="1">73</td>
                        <td rowspan="1" colspan="1">9784.9 (5995.4)</td>
                        <td rowspan="1" colspan="1">8580.0</td>
                        <td rowspan="1" colspan="1">5443.0, 11 972.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> pMMR</td>
                        <td rowspan="1" colspan="1">504</td>
                        <td rowspan="1" colspan="1">9762.8 (5955.6)</td>
                        <td rowspan="1" colspan="1">8303.0</td>
                        <td rowspan="1" colspan="1">5279.5, 12 687.5</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn1">
                      <label>a</label>
                      <p>Kruskal-Wallis rank sum test. All statistical tests were 2-sided. BMI = body mass index; dMMR = deficient mismatch repair; MMR = mismatch repair; pMMR = proficient mismatch repair; TILs = tumor-infiltrating lymphocytes; Q = Quartile.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>A statistically significant reduction in plasma 25(OH)D, as a continuous variable, was found in Blacks vs Whites or Asians (<italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>.001) (<xref rid="pkab070-T2" ref-type="table">Table 2</xref>). Differences by sex were statistically, but not clinically significant. A statistically significant decrease in 25(OH)D levels was found in the relatively few patients with poor performance status. Insufficiency of 25(OH)D (&lt;0 ng/mL) was detected in 49% (291 of 600) of study participants. Consistent results were found for the dichotomous 25(OH)D by patient race (<italic toggle="yes">P</italic> &lt; .001) and sex (<italic toggle="yes">P</italic> &lt; .03) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>, available online). Specifically, insufficiency of 25(OH)D was more common in Blacks vs Whites or Asians (73.6% vs 45% vs 53.6%) and in women vs men (53.2% vs 44.3%), with both achieving statistical significance. 25(OH)D was not statistically significantly associated with BMI or adiponectin level. Neither the association of the continuous nor of the dichotomous 25(OH)D level with TIL density achieved statistical significance (<xref rid="pkab070-T2" ref-type="table">Table 2</xref>; <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>, available online).</p>
                <table-wrap position="float" id="pkab070-T2">
                  <label>Table 2.</label>
                  <caption>
                    <p>Association between continuous vitamin D level and clinicopathological variables</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="2" colspan="1">Variable</th>
                        <th rowspan="2" colspan="1">No.</th>
                        <th colspan="3" rowspan="1">Vitamin D level, ng/mL<hr/></th>
                        <th rowspan="2" colspan="1">
                          <italic toggle="yes">P</italic>
                          <xref rid="tblfn2" ref-type="table-fn">
                            <sup>a</sup>
                          </xref>
                        </th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1">Mean (SD)</th>
                        <th rowspan="1" colspan="1">Median</th>
                        <th rowspan="1" colspan="1">Q1, Q3</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Age, y</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.74</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> ≤65</td>
                        <td rowspan="1" colspan="1">420</td>
                        <td rowspan="1" colspan="1">30.9 (10.2)</td>
                        <td rowspan="1" colspan="1">30.3</td>
                        <td rowspan="1" colspan="1">24.0, 35.9</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> &gt;65</td>
                        <td rowspan="1" colspan="1">180</td>
                        <td rowspan="1" colspan="1">30.7 (10.3)</td>
                        <td rowspan="1" colspan="1">30.0</td>
                        <td rowspan="1" colspan="1">23.2, 36.5</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Race</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Asian</td>
                        <td rowspan="1" colspan="1">28</td>
                        <td rowspan="1" colspan="1">30.7 (9.9)</td>
                        <td rowspan="1" colspan="1">29.6</td>
                        <td rowspan="1" colspan="1">25.0, 35.7</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Black</td>
                        <td rowspan="1" colspan="1">53</td>
                        <td rowspan="1" colspan="1">25.2 (8.7)</td>
                        <td rowspan="1" colspan="1">23.1</td>
                        <td rowspan="1" colspan="1">18.9, 30.3</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> White</td>
                        <td rowspan="1" colspan="1">502</td>
                        <td rowspan="1" colspan="1">31.5 (10.3)</td>
                        <td rowspan="1" colspan="1">31.0</td>
                        <td rowspan="1" colspan="1">24.2, 36.7</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Sex</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.03</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Female</td>
                        <td rowspan="1" colspan="1">284</td>
                        <td rowspan="1" colspan="1">30.0 (10.9)</td>
                        <td rowspan="1" colspan="1">29.2</td>
                        <td rowspan="1" colspan="1">22.7, 35.7</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Male</td>
                        <td rowspan="1" colspan="1">316</td>
                        <td rowspan="1" colspan="1">31.5 (9.5)</td>
                        <td rowspan="1" colspan="1">30.8</td>
                        <td rowspan="1" colspan="1">25.6, 36.4</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">BMI</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.09</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Underweight</td>
                        <td rowspan="1" colspan="1">10</td>
                        <td rowspan="1" colspan="1">30.7 (8.8)</td>
                        <td rowspan="1" colspan="1">32.4</td>
                        <td rowspan="1" colspan="1">26.2, 35.6</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Normal</td>
                        <td rowspan="1" colspan="1">159</td>
                        <td rowspan="1" colspan="1">31.8 (10.2)</td>
                        <td rowspan="1" colspan="1">30.6</td>
                        <td rowspan="1" colspan="1">24.9, 36.6</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overweight</td>
                        <td rowspan="1" colspan="1">210</td>
                        <td rowspan="1" colspan="1">31.3 (9.9)</td>
                        <td rowspan="1" colspan="1">31.5</td>
                        <td rowspan="1" colspan="1">23.4, 37.5</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Obese</td>
                        <td rowspan="1" colspan="1">218</td>
                        <td rowspan="1" colspan="1">29.6 (10.5)</td>
                        <td rowspan="1" colspan="1">29.3</td>
                        <td rowspan="1" colspan="1">23.1, 34.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">T stage</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.51</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> T1 or T2</td>
                        <td rowspan="1" colspan="1">96</td>
                        <td rowspan="1" colspan="1">31.9 (10.9)</td>
                        <td rowspan="1" colspan="1">31.0</td>
                        <td rowspan="1" colspan="1">24.6, 38.3</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> T3</td>
                        <td rowspan="1" colspan="1">441</td>
                        <td rowspan="1" colspan="1">30.7 (10.1)</td>
                        <td rowspan="1" colspan="1">30.2</td>
                        <td rowspan="1" colspan="1">23.5, 35.9</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> T4</td>
                        <td rowspan="1" colspan="1">63</td>
                        <td rowspan="1" colspan="1">29.9 (9.3)</td>
                        <td rowspan="1" colspan="1">29.8</td>
                        <td rowspan="1" colspan="1">23.5, 34.5</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">N stage</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.60</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 1-3</td>
                        <td rowspan="1" colspan="1">365</td>
                        <td rowspan="1" colspan="1">31.1 (11.0)</td>
                        <td rowspan="1" colspan="1">30.2</td>
                        <td rowspan="1" colspan="1">23.7, 36.6</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 4</td>
                        <td rowspan="1" colspan="1">235</td>
                        <td rowspan="1" colspan="1">30.3 (8.8)</td>
                        <td rowspan="1" colspan="1">30.2</td>
                        <td rowspan="1" colspan="1">23.7, 35.2</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Performance status</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.047</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 0</td>
                        <td rowspan="1" colspan="1">453</td>
                        <td rowspan="1" colspan="1">31.3 (10.4)</td>
                        <td rowspan="1" colspan="1">30.8</td>
                        <td rowspan="1" colspan="1">24.2, 36.7</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 1</td>
                        <td rowspan="1" colspan="1">141</td>
                        <td rowspan="1" colspan="1">29.3 (9.5)</td>
                        <td rowspan="1" colspan="1">29.2</td>
                        <td rowspan="1" colspan="1">22.7, 34.9</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 2</td>
                        <td rowspan="1" colspan="1">6</td>
                        <td rowspan="1" colspan="1">26.0 (4.5)</td>
                        <td rowspan="1" colspan="1">25.8</td>
                        <td rowspan="1" colspan="1">22.7, 28.1</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Tumor location</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.34</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Left</td>
                        <td rowspan="1" colspan="1">286</td>
                        <td rowspan="1" colspan="1">31.4 (10.8)</td>
                        <td rowspan="1" colspan="1">30.7</td>
                        <td rowspan="1" colspan="1">24.2, 36.9</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Right</td>
                        <td rowspan="1" colspan="1">303</td>
                        <td rowspan="1" colspan="1">30.4 (9.6)</td>
                        <td rowspan="1" colspan="1">29.8</td>
                        <td rowspan="1" colspan="1">23.6, 35.7</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">TILs</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.07</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Low (≤3)</td>
                        <td rowspan="1" colspan="1">248</td>
                        <td rowspan="1" colspan="1">31.4 (10.7)</td>
                        <td rowspan="1" colspan="1">30.2</td>
                        <td rowspan="1" colspan="1">24.2, 37.6</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> High (&gt;3)</td>
                        <td rowspan="1" colspan="1">100</td>
                        <td rowspan="1" colspan="1">29.1 (9.4)</td>
                        <td rowspan="1" colspan="1">29.2</td>
                        <td rowspan="1" colspan="1">22.6, 34.2</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <italic toggle="yes">BRAF</italic>
                        </td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.82</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Mutant</td>
                        <td rowspan="1" colspan="1">198</td>
                        <td rowspan="1" colspan="1">31.4 (11.5)</td>
                        <td rowspan="1" colspan="1">30.1</td>
                        <td rowspan="1" colspan="1">23.7, 36.5</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Wild type</td>
                        <td rowspan="1" colspan="1">357</td>
                        <td rowspan="1" colspan="1">30.5 (9.6)</td>
                        <td rowspan="1" colspan="1">30.3</td>
                        <td rowspan="1" colspan="1">23.4, 36.0</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <italic toggle="yes">KRAS</italic>
                        </td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.47</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Mutant</td>
                        <td rowspan="1" colspan="1">73</td>
                        <td rowspan="1" colspan="1">29.8 (10.1)</td>
                        <td rowspan="1" colspan="1">30.2</td>
                        <td rowspan="1" colspan="1">22.5, 36.1</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Wild type</td>
                        <td rowspan="1" colspan="1">482</td>
                        <td rowspan="1" colspan="1">31.0 (10.3)</td>
                        <td rowspan="1" colspan="1">30.2</td>
                        <td rowspan="1" colspan="1">23.7, 36.1</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">MMR</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.90</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> dMMR</td>
                        <td rowspan="1" colspan="1">73</td>
                        <td rowspan="1" colspan="1">30.6 (10.2)</td>
                        <td rowspan="1" colspan="1">31.2</td>
                        <td rowspan="1" colspan="1">22.7, 36.1</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> pMMR</td>
                        <td rowspan="1" colspan="1">504</td>
                        <td rowspan="1" colspan="1">30.8 (10.3)</td>
                        <td rowspan="1" colspan="1">30.1</td>
                        <td rowspan="1" colspan="1">23.7, 35.9</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn2">
                      <label>a</label>
                      <p>Kruskal-Wallis rank sum test. All statistical tests were 2-sided. BMI = body mass index; dMMR = deficient mismatch repair; MMR = mismatch repair; pMMR = proficient mismatch repair; TILs = tumor-infiltrating lymphocytes; Q = Quartile.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec>
                <title>Association of Plasma Adiponectin and 25(OH)D Levels With Patient Clinical Outcome</title>
                <p>Univariately, plasma adiponectin was not statistically significantly associated with DFS as a dichotomous variable (cut at median; hazard ratio [HR]<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>0.98, 95% confidence interval [CI]<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>0.74 to 1.29; <italic toggle="yes">P</italic> = .88) shown in a Kaplan Meier plot (<xref rid="pkab070-F2" ref-type="fig">Figure 2, A</xref>) or a continuous variable shown by cubic spline (<xref rid="pkab070-F2" ref-type="fig">Figure 2, C</xref>). No association was found between adiponectin and OS (HR = 0.90, 95% CI<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>0.66 to 1.22; <italic toggle="yes">P</italic> = .49) or TTR (HR = 1.03, 95% CI<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>0.75 to 1.34; <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>1.00) (data not shown). We then constructed a multivariable model that included adiponectin and potential confounding variables based on observed associations (<xref rid="pkab070-T1" ref-type="table">Table 1</xref>) and the literature. The association of adiponectin with patient DFS did not achieve statistical significance as a continuous (adjusted HR [HR<sub>adj</sub>]<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>1.01, 95% CI<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>0.98 to 1.04; adjusted <italic toggle="yes">P</italic> [<italic toggle="yes">P</italic><sub>adj</sub>] = .57) or a dichotomous (data not shown) variable in a multivariable model adjusted for treatment arm, race, BMI, TILs, and N stage (<xref rid="pkab070-T3" ref-type="table">Table 3</xref>). In this model, statistically significantly poorer DFS was observed for tumors with low vs high TILs (HR<sub>adj</sub> = 1.77, 95% CI<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>1.11 to 2.81; <italic toggle="yes">P</italic><sub>adj</sub> = .02) and N2 vs N1 stage (HR<sub>adj</sub> = 2.08, 95% CI<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>1.44 to 2.99; <italic toggle="yes">P</italic><sub>adj</sub> &lt; .001) (<xref rid="pkab070-T3" ref-type="table">Table 3</xref>). Adiponectin was not statistically significantly associated with OS or TTR as either a continuous or dichotomous variable.</p>
                <fig position="float" id="pkab070-F2">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Univariate association of postsurgical plasma adiponectin and 25(OH)D with DFS in patients with stage III colon cancer. Variables are analyzed as dichotomous using Kaplan-Meier plots (<bold>A, B</bold>) or as continuous using a relative risk model with cubic splines (<bold>C, D</bold>). Adiponectin level was dichotomized at the median value (<bold>A</bold>), and 25(OH)D level was dichotomized as insufficient (&lt;30 ng/mL) vs sufficient (<underline>&gt;</underline>30 ng/mL) (<bold>B</bold>). All statistical tests were 2-sided. 25(OH)D = 25-hydroxyvitamin D; CI = confidence interval; d.f. = degrees of freedom; DFS = disease-free survival; HR = hazard ratio.</p>
                  </caption>
                  <graphic xlink:href="pkab070f2" position="float"/>
                </fig>
                <table-wrap position="float" id="pkab070-T3">
                  <label>Table 3.</label>
                  <caption>
                    <p>Multivariable analysis of plasma adiponectin and patient disease-free survival</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1">Variable</th>
                        <th rowspan="1" colspan="1">Events/Total</th>
                        <th rowspan="1" colspan="1">HR (95% CI)</th>
                        <th rowspan="1" colspan="1">
                          <italic toggle="yes">P</italic>
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Adiponectin (step size: 1000)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">1.01 (0.98 to 1.04)</td>
                        <td rowspan="1" colspan="1">.57<xref rid="tblfn3" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Treatment arm</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> FOLFOX</td>
                        <td rowspan="1" colspan="1">56/169</td>
                        <td rowspan="1" colspan="1">Referent</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> FOLFOX + cetuximab</td>
                        <td rowspan="1" colspan="1">66/169</td>
                        <td rowspan="1" colspan="1">1.09 (0.76 to 1.58)</td>
                        <td rowspan="1" colspan="1">.63<xref rid="tblfn3" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Race</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.34<xref rid="tblfn4" ref-type="table-fn"><sup>b</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Asian</td>
                        <td rowspan="1" colspan="1">3/14</td>
                        <td rowspan="1" colspan="1">0.47 (0.15 to 1.51)</td>
                        <td rowspan="1" colspan="1">.20<xref rid="tblfn3" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Black</td>
                        <td rowspan="1" colspan="1">9/22</td>
                        <td rowspan="1" colspan="1">1.09 (0.55 to 2.18)</td>
                        <td rowspan="1" colspan="1">.81<xref rid="tblfn3" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> White</td>
                        <td rowspan="1" colspan="1">110/302</td>
                        <td rowspan="1" colspan="1">Referent</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">BMI</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.41<xref rid="tblfn4" ref-type="table-fn"><sup>b</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Normal</td>
                        <td rowspan="1" colspan="1">28/88</td>
                        <td rowspan="1" colspan="1">Referent</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Obese</td>
                        <td rowspan="1" colspan="1">54/133</td>
                        <td rowspan="1" colspan="1">1.50 (0.93 to 2.41)</td>
                        <td rowspan="1" colspan="1">.10<xref rid="tblfn3" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overweight</td>
                        <td rowspan="1" colspan="1">38/112</td>
                        <td rowspan="1" colspan="1">1.26 (0.77 to 2.07)</td>
                        <td rowspan="1" colspan="1">.36<xref rid="tblfn3" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Underweight</td>
                        <td rowspan="1" colspan="1">2/5</td>
                        <td rowspan="1" colspan="1">1.02 (0.23 to 4.49)</td>
                        <td rowspan="1" colspan="1">.97<xref rid="tblfn3" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">TILs</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Low (≤3)</td>
                        <td rowspan="1" colspan="1">99/241</td>
                        <td rowspan="1" colspan="1">1.77 (1.11 to 2.81)</td>
                        <td rowspan="1" colspan="1">.02<xref rid="tblfn3" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> High (&gt;3)</td>
                        <td rowspan="1" colspan="1">23/97</td>
                        <td rowspan="1" colspan="1">Referent</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">N Stage</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> N1</td>
                        <td rowspan="1" colspan="1">59/214</td>
                        <td rowspan="1" colspan="1">Referent</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> N2</td>
                        <td rowspan="1" colspan="1">63/124</td>
                        <td rowspan="1" colspan="1">2.08 (1.44 to 2.99)</td>
                        <td rowspan="1" colspan="1">&lt;.001<xref rid="tblfn3" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn3">
                      <label>a</label>
                      <p>Covariate Wald <italic toggle="yes">P</italic> value. All tests were 2-sided. BMI = body mass index; CI = confidence interval; HR = hazard ratio; TILs = tumor-infiltrating lymphocytes.</p>
                    </fn>
                    <fn id="tblfn4">
                      <label>b</label>
                      <p>Type 3 likelihood-ratio <italic toggle="yes">P</italic> value. All tests were 2-sided.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Univariately, insufficient vs sufficient 25(OH)D was not statistically significantly associated with DFS (HR = 1.12, 95% CI<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>0.85 to 1.47; <italic toggle="yes">P</italic> = .44) (<xref rid="pkab070-F2" ref-type="fig">Figure 2, B</xref>), OS (HR = 1.20, 95% CI<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>0.88 to 1.63; <italic toggle="yes">P</italic> = .25), or TTR (HR = 1.11, 95% CI<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>0.83 to 1.49; <italic toggle="yes">P</italic> = .47). Similarly, the continuous 25(OH)D was not statistically significantly associated with DFS (<xref rid="pkab070-F2" ref-type="fig">Figure 2, D</xref>) or with other outcome variables. In contrast, low vs high TIL density was associated with poorer patient DFS (HR = 1.89, 95% CI<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>1.20 to 2.94; <italic toggle="yes">P</italic> = .005) that achieved statistical significance with 3-year survival rates of 65.4% vs 80.5%, respectively. In a multivariable model that included potential confounders, 25(OH)D as a continuous variable was not associated with patient DFS (HR<sub>adj</sub><italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>1.00, 95% CI<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>0.98 to 1.02; <italic toggle="yes">P</italic><sub>adj</sub> = 1.00) (<xref rid="pkab070-T4" ref-type="table">Table 4</xref>) or with OS or TTR (data not shown). In this model, TILs (low vs high: HR = 1.77, 95% CI<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>1.11 to 2.83; <italic toggle="yes">P</italic> = .02) and N stage (HR = 2.10, 95% CI<italic toggle="yes"> </italic>=<italic toggle="yes"> </italic>1.46 to 3.02; <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>.001) were statistically significantly associated with DFS (<xref rid="pkab070-T4" ref-type="table">Table 4</xref>). We also examined 25(OH)D as a dichotomous variable whereby insufficiency (&lt;30 ng/mL) was not associated with a statistically significant difference in DFS, OS, or TTR (data not shown). Furthermore, we dichotomized 25(OH)D according to the World Health Organization definition of vitamin D deficiency (&lt;20 ng/mL) and found that it was again not statistically significantly prognostic for DFS (data not shown).</p>
                <table-wrap position="float" id="pkab070-T4">
                  <label>Table 4.</label>
                  <caption>
                    <p>Multivariate analysis of plasma 25-hydroxyvitamin D and patient disease-free survival</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1">Variable</th>
                        <th rowspan="1" colspan="1">Events/Total</th>
                        <th rowspan="1" colspan="1">HR (95% CI)</th>
                        <th rowspan="1" colspan="1">
                          <italic toggle="yes">P</italic>
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Vitamin D ng/mL (step size: 1)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">1.00 (0.98 to 1.02)</td>
                        <td rowspan="1" colspan="1">1.00<xref rid="tblfn5" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Treatment arm</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> FOLFOX</td>
                        <td rowspan="1" colspan="1">56/169</td>
                        <td rowspan="1" colspan="1">Referent</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> FOLFOX + cetuximab</td>
                        <td rowspan="1" colspan="1">66/169</td>
                        <td rowspan="1" colspan="1">1.11 (0.77 to 1.59)</td>
                        <td rowspan="1" colspan="1">.58<xref rid="tblfn5" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Race</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.32<xref rid="tblfn6" ref-type="table-fn"><sup>b</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Asian</td>
                        <td rowspan="1" colspan="1">3/14</td>
                        <td rowspan="1" colspan="1">0.46 (0.14 to 1.46)</td>
                        <td rowspan="1" colspan="1">.19<xref rid="tblfn5" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Black</td>
                        <td rowspan="1" colspan="1">9/22</td>
                        <td rowspan="1" colspan="1">1.07 (0.53 to 2.16)</td>
                        <td rowspan="1" colspan="1">.85<xref rid="tblfn5" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> White</td>
                        <td rowspan="1" colspan="1">110/302</td>
                        <td rowspan="1" colspan="1">Referent</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">BMI</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">.46<xref rid="tblfn6" ref-type="table-fn"><sup>b</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Normal</td>
                        <td rowspan="1" colspan="1">28/88</td>
                        <td rowspan="1" colspan="1">Referent</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Obese</td>
                        <td rowspan="1" colspan="1">54/133</td>
                        <td rowspan="1" colspan="1">1.45 (0.91 to 2.30)</td>
                        <td rowspan="1" colspan="1">.12<xref rid="tblfn5" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overweight</td>
                        <td rowspan="1" colspan="1">38/112</td>
                        <td rowspan="1" colspan="1">1.24 (0.76 to 2.03)</td>
                        <td rowspan="1" colspan="1">.39<xref rid="tblfn5" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Underweight</td>
                        <td rowspan="1" colspan="1">2/5</td>
                        <td rowspan="1" colspan="1">1.13 (0.27 to 4.78)</td>
                        <td rowspan="1" colspan="1">.87<xref rid="tblfn5" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">TILs</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Low (≤3)</td>
                        <td rowspan="1" colspan="1">99/241</td>
                        <td rowspan="1" colspan="1">1.77 (1.11 to 2.83)</td>
                        <td rowspan="1" colspan="1">.02<xref rid="tblfn5" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> High (&gt;3)</td>
                        <td rowspan="1" colspan="1">23/97</td>
                        <td rowspan="1" colspan="1">Referent</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">N Stage</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> N1</td>
                        <td rowspan="1" colspan="1">59/214</td>
                        <td rowspan="1" colspan="1">Referent</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> N2</td>
                        <td rowspan="1" colspan="1">63/124</td>
                        <td rowspan="1" colspan="1">2.10 (1.46 to 3.02)</td>
                        <td rowspan="1" colspan="1">&lt;.001<xref rid="tblfn5" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn5">
                      <label>a</label>
                      <p>Covariate Wald <italic toggle="yes">P</italic> value. All tests were 2-sided. BMI = body mass index; CI = confidence interval; HR = hazard ratio; TILs = tumor-infiltrating lymphocytes.</p>
                    </fn>
                    <fn id="tblfn6">
                      <label>b</label>
                      <p>Type 3 likelihood-ratio <italic toggle="yes">P</italic> value. All tests were 2-sided.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>We constructed 3-way interaction models that examined the association of adiponectin and 25(OH)D (adjusting for race and BMI) by TILs and N stage subgroups. No statistically significant relationships were found indicating that the observed associations were not interdependent. Of note, TIL density did not differ by BMI category (<italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>.50) (data not shown). Furthermore and given observed differences in adiponectin and 25(OH)D levels by patient sex (<xref rid="pkab070-T1" ref-type="table">Tables 1</xref> and <xref rid="pkab070-T2" ref-type="table">2</xref>), analysis of 25(OH)D with clinical outcome variables (TTR, DFS, OS) by sex or TIL density failed to reveal any statistically significant associations after adjustment for covariates.</p>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>Discussion</title>
              <p>We analyzed adiponectin and 25(OH)D in postsurgical blood samples from patients with stage III colon cancer treated in a phase III trial of adjuvant chemotherapy. Based on preclinical data suggesting that adiponectin may influence the host inflammatory response to cancer, we determined the association of adiponectin with TIL density in the tumor immune microenvironment. Lower adiponectin levels were associated with a statistically significant increase in TIL density, indicating an inverse relationship between adiponectin and antitumor immunity. This result is consistent with data in a murine model where adiponectin deficiency was associated with tumors with an increased inflammatory infiltrate compared with tumors in nonadiponectin-deficient mice (<xref rid="pkab070-B27" ref-type="bibr">27</xref>). Adiponectin has been shown to reduce T-cell and B-cell recruitment, induce production of anti-inflammatory cytokines such as IL-10 and an inhibitor of metalloproteinase-1, and inhibit pro-inflammatory chemokines such as IL-6 and TNF-α (<xref rid="pkab070-B5" ref-type="bibr">5</xref>,<xref rid="pkab070-B28" ref-type="bibr">28</xref>). Furthermore, adiponectin was shown to impede inflammation-induced tumorigenesis (<xref rid="pkab070-B29" ref-type="bibr">29</xref>). In contrast to adiponectin, we did not find a statistically significant association between the level of plasma 25(OH)D and TIL density. In another report, higher plasma 25(OH)D levels were associated with a lower risk of CRCs with a high density of CD3<sup>+</sup> T cells (<xref rid="pkab070-B18" ref-type="bibr">18</xref>). We found that lower adiponectin levels were statistically significantly associated with cancers showing fewer regional lymph node metastases (N1 vs N2 stage). Relevant to this finding is our prior observation of statistically significantly higher TIL densities in N1 vs N2 stage colon cancers (<italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>.0001) (<xref rid="pkab070-B25" ref-type="bibr">25</xref>), yet no interaction was found between TIL densities, N stage, and adiponectin in the current study.</p>
              <p>Importantly, we confirmed the reported inverse relationship of adiponectin level to BMI in our dataset (<xref rid="pkab070-B30" ref-type="bibr">30</xref>,<xref rid="pkab070-B31" ref-type="bibr">31</xref>). A statistically significant and inverse relationship between adiponectin and BMI category was observed, with the lowest adiponectin levels found among obese patients. Although adiponectin is exclusively secreted by adipocytes, its paradoxical reduction in obesity may reflect reduced secretion from visceral fat rather than subcutaneous fat. Hypertrophic adipocytes synthesize monocyte chemotactic protein-1 leading to infiltration of macrophages in white adipose tissue accompanied by elevated local TNF-α and increased free fatty acid concentrations that suppress adiponectin secretion (<xref rid="pkab070-B32" ref-type="bibr">32</xref>). Other factors may include dysregulation of the adiponectin gene (<italic toggle="yes">ADIPOQ</italic>) in obesity (<xref rid="pkab070-B33" ref-type="bibr">33</xref>).</p>
              <p>We observed differences in adiponectin by sex whereby men had statistically significantly lower levels compared with women. This observation may be explained by higher serum androgens in men (<xref rid="pkab070-B34" ref-type="bibr">34</xref>), and the finding of increased adiponectin levels in older vs younger men may be due to an age-related decline in testosterone levels. In this regard, adiponectin levels were shown to decrease after testosterone administration in hypogonadal men (<xref rid="pkab070-B35" ref-type="bibr">35</xref>). In women, adiponectin has been shown to decrease with the transition to menopause (<xref rid="pkab070-B36" ref-type="bibr">36</xref>). We found statistically significantly lower adiponectin levels among Blacks compared with Whites or Asians, which was not explained by differences in BMI by race. However, lower adiponectin levels among Blacks vs Whites was attributed to adiponectin’s association with BMI in the population-based race-ethnic Northern Manhattan Study (<xref rid="pkab070-B37" ref-type="bibr">37</xref>). Differences in adiponectin levels may also have a hereditary component, and further analysis of single nucleotide polymorphisms in adiponectin-related genes may provide further insight (<xref rid="pkab070-B38" ref-type="bibr">38</xref>).</p>
              <p>Whereas plasma adiponectin was associated with vitamin D levels in nonCRC patients (<xref rid="pkab070-B11" ref-type="bibr">11</xref>), no such relationship was observed in our CRC cohort. We observed that nearly one-half of patients were vitamin D insufficient (&lt;30 ng/mL), which far exceeds the 8% prevalence of vitamin D insufficiency in the US general population (<xref rid="pkab070-B39" ref-type="bibr">39</xref>). We found a higher rate of vitamin D insufficiency among Black vs White or Asian. In addition to dietary factors and sunlight exposure, race can influence vitamin D status in that melanin in skin reduces the rate of vitamin D biosynthesis (<xref rid="pkab070-B12" ref-type="bibr">12</xref>,<xref rid="pkab070-B40" ref-type="bibr">40</xref>). Furthermore, racial differences in the prevalence of common genetic polymorphisms can influence vitamin D levels; for example, Blacks are more likely to have the T allele at rs7041 and less likely to have the A allele at rs4588 vs Whites (<xref rid="pkab070-B41" ref-type="bibr">41</xref>). Differences by sex for the continuous vitamin D variable were modest; however, vitamin D insufficiency was statistically significantly more common in women vs men, which is consistent with an increased prevalence of hypovitaminosis D in women especially after menopause (<xref rid="pkab070-B42" ref-type="bibr">42</xref>).</p>
              <p>Despite the inverse association of adiponectin levels and TIL densities that we observed, adiponectin was not statistically significantly associated with patient DFS, OS, or TTR univariately or after adjustment for potential confounders. To our knowledge, these are the first data for postsurgical adiponectin and clinical outcome in CRC patients. Adiponectin at diagnosis of CRC was also not prognostic in a prospective study in 344 consecutive cases (<xref rid="pkab070-B10" ref-type="bibr">10</xref>). Regarding prediagnostic adiponectin, 2 large observational cohorts found a statistically significant and independent association of higher levels with reduced CRC-specific and OS that was more evident in patients with metastatic disease (<xref rid="pkab070-B9" ref-type="bibr">9</xref>). A potential explanation may be an elevation of adiponectin during weight loss, which is a known predictor of poor prognosis in cancer patients. Adiponectin is an insulin-sensitizing hormone, and low levels are associated with an increased risk of type 2 diabetes independent of other risk factors (<xref rid="pkab070-B43" ref-type="bibr">43</xref>). Adiponectin mediates its insulin-sensitizing effect through activation of AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor–alpha pathways with resultant suppression of tumor growth in animal models (<xref rid="pkab070-B44" ref-type="bibr">44</xref>). As with adiponectin, plasma 25(OH)D was not statistically significantly associated with clinical outcome variables in our cohort. However, a study of resected stage III colon cancer patients found that a higher predicted 25(OH)D score was associated with improved survival outcomes (<xref rid="pkab070-B16" ref-type="bibr">16</xref>). Of note, 25(OH)D scores were calculated based on serial patient questionnaire data, but not measurements in blood samples. Another study of 1598 patients with stage I to III CRC found that patients with the highest vs lowest tertile of postoperative plasma 25(OH)D levels had lower CRC-specific and all-cause mortality that achieved statistical significance (<xref rid="pkab070-B45" ref-type="bibr">45</xref>). 25(OH)D levels, however, were not prognostic in patients with stage IV CRC (n = 515) from a clinical trial cohort (<xref rid="pkab070-B46" ref-type="bibr">46</xref>). We interpret our results and those in stage IV cancers to suggest that any effect of vitamin D on prognosis is attenuated or lost once the disease has metastasized either to regional lymph nodes (stage III) or to distant sites (stage IV). In contrast, a statistically significant association of TILs with prognosis was found in our cohort with low vs high TILs being associated with poorer patient survival as we previously reported (<xref rid="pkab070-B22" ref-type="bibr">22</xref>,<xref rid="pkab070-B25" ref-type="bibr">25</xref>).</p>
              <p>Strengths of our study include same stage patients with uniform treatment in a clinical trial with long-term and meticulous follow-up data. Blood was collected from all patients prior to initiation of chemotherapy, such that the time period between biomarker sampling and initiation of adjuvant treatment was relatively constant. Whereas other studies have used cancer prediagnosis measurements (<xref rid="pkab070-B47" ref-type="bibr">47</xref>), our study is the first to examine postdiagnostic plasma adiponectin levels in relation to survival outcomes in CRC patients. Study limitations include retrospective biomarker analysis that was not prespecified and the single assay timepoint. Importantly, measurement of 25(OH)D at a single timepoint was shown to provide an accurate assessment of an individual’s long-term vitamin D status (<xref rid="pkab070-B48" ref-type="bibr">48</xref>). Similarly, adiponectin levels were shown to remain stable over time (<xref rid="pkab070-B49" ref-type="bibr">49</xref>). We cannot exclude the possibility that the modest sample size of our study may have contributed to the failure to detect a prognostic effect for either biomarker.</p>
              <p>In conclusion, we identified a novel inverse association of adiponectin with the intratumoral antitumor immune response indicated by TIL density. Validation of this association in an independent cohort of patients with CRC is warranted. In contrast to TILs, neither adiponectin nor 25(OH)D was found to be prognostic.</p>
            </sec>
            <sec>
              <title>Funding</title>
              <p>Research reported in this publication was supported by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under award numbers U10CA180821, U10CA180882; U10CA180863, CCSRI 021039 (CCTG); U10CA180868 (NRG); U10CA180888, and UG1CA233163 (SWOG). NCCTG N0147 received funds from Sanofi Aventis. The study was also supported by NCI R01CA210509 (to FAS).</p>
            </sec>
            <sec>
              <title>Notes</title>
              <p><bold>Role of the funders:</bold> The funders had no role in the design of the study or in the data collection, analysis, or interpretation. Furthermore, the funders did not participate in the writing of the manuscript or in the decision to submit the manuscript for publication.</p>
              <p><bold>Disclosures:</bold> FAS is a co-inventor of intellectual property with Roche Ventana Medical Systems (Tucson, AZ) and may receive royalties paid to Mayo Clinic. No other relevant conflicts related to the subject matter of this manuscript are reported by the study authors.</p>
              <p><bold>Author contributions:</bold> Study conceptualization: FAS. Data curation: QS. Formal analysis: SBJ, NRF, QS. Funding acquisition: FAS, SRA. Investigation: TCS, RMG, SJC, SG, MSK, SN, AFS, BNJ, MNP, SRA. Methodology: MNP. Project administration/supervision: FAS. Writing: original draft: FAS. Writing-review and editing: all authors.</p>
            </sec>
            <sec sec-type="data-availability">
              <title>Data Availability</title>
              <p>Data from published Alliance or North Central Cancer Treatment Group (NCCTG) trials can be accessed by submission of an Alliance Data Sharing Request Form (<email>concepts@allianceNCTN.org</email>). Requests to utilize biomarker data published in this manuscript should also be directed to the corresponding author.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="sup1" position="float" content-type="local-data">
                <label>pkab070_Supplementary_Data</label>
                <media xlink:href="pkab070_supplementary_data.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ref-list id="ref1">
              <title>References</title>
              <ref id="pkab070-B1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gupta</surname><given-names>S</given-names></string-name>, <string-name><surname>Coronado</surname><given-names>GD</given-names></string-name>, <string-name><surname>Argenbright</surname><given-names>K</given-names></string-name></person-group>, <etal>et al</etal><article-title>Colorectal cancer statistics, 2020</article-title>. <source>CA Cancer J Clin</source>. <year>2020</year>;<volume>70</volume>(<issue>4</issue>):<fpage>283</fpage>–<lpage>164</lpage>.<pub-id pub-id-type="pmid">32583884</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hanyuda</surname><given-names>A</given-names></string-name>, <string-name><surname>Lee</surname><given-names>DH</given-names></string-name>, <string-name><surname>Ogino</surname><given-names>S</given-names></string-name></person-group>, <etal>et al</etal><article-title>Long-term status of predicted body fat percentage, body mass index and other anthropometric factors with risk of colorectal carcinoma: two large prospective cohort studies in the US</article-title>. <source>Int J Cancer</source>. <year>2020</year>;<volume>146</volume>(<issue>9</issue>):<fpage>2383</fpage>–<lpage>2393</lpage>.<pub-id pub-id-type="pmid">31276608</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Folco</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Rocha</surname><given-names>VZ</given-names></string-name>, <string-name><surname>López-Ilasaca</surname><given-names>M</given-names></string-name>, <string-name><surname>Libby</surname><given-names>P.</given-names></string-name></person-group><article-title>Adiponectin inhibits pro-inflammatory signaling in human macrophages independent of interleukin-10</article-title>. <source>J Biol Chem</source>. <year>2009</year>;<volume>284</volume>(<issue>38</issue>):<fpage>25569</fpage>–<lpage>25575</lpage>.<pub-id pub-id-type="pmid">19617629</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>KY</given-names></string-name>, <string-name><surname>Kim</surname><given-names>JK</given-names></string-name>, <string-name><surname>Han</surname><given-names>SH</given-names></string-name></person-group>, <etal>et al</etal><article-title>Adiponectin is a negative regulator of NK cell cytotoxicity</article-title>. <source>J Immunol</source>. <year>2006</year>;<volume>176</volume>(<issue>10</issue>):<fpage>5958</fpage>–<lpage>5964</lpage>.<pub-id pub-id-type="pmid">16670304</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luo</surname><given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname><given-names>M.</given-names></string-name></person-group><article-title>Adiponectin: a versatile player of innate immunity</article-title>. <source>J Mol Cell Biol</source>. <year>2016</year>;<volume>8</volume>(<issue>2</issue>):<fpage>120</fpage>–<lpage>128</lpage>.<pub-id pub-id-type="pmid">26993045</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname><given-names>M</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name><surname>Wu</surname><given-names>K</given-names></string-name></person-group>, <etal>et al</etal><article-title>Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study</article-title>. <source>Cancer Prev Res (Phila)</source>. <year>2013</year>;<volume>6</volume>(<issue>9</issue>):<fpage>875</fpage>–<lpage>885</lpage>.<pub-id pub-id-type="pmid">23872505</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>An</surname><given-names>W</given-names></string-name>, <string-name><surname>Bai</surname><given-names>Y</given-names></string-name>, <string-name><surname>Deng</surname><given-names>SX</given-names></string-name></person-group>, <etal>et al</etal><article-title>Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis</article-title>. <source>Eur J Cancer Prev</source>. <year>2012</year>;<volume>21</volume>(<issue>2</issue>):<fpage>126</fpage>–<lpage>133</lpage>.<pub-id pub-id-type="pmid">21960184</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname><given-names>W</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Li</surname><given-names>N</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name></person-group><article-title>Low circulating total adiponectin, especially its non-high-molecular weight fraction, represents a promising risk factor for colorectal cancer: a meta-analysis</article-title>. <source>Onco Targets Ther</source>. <year>2018</year>;<volume>11</volume>:<fpage>2519</fpage>–<lpage>2531</lpage>.<pub-id pub-id-type="pmid">29765231</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chong</surname><given-names>DQ</given-names></string-name>, <string-name><surname>Mehta</surname><given-names>RS</given-names></string-name>, <string-name><surname>Song</surname><given-names>M</given-names></string-name></person-group>, <etal>et al</etal><article-title>Prediagnostic plasma adiponectin and survival among patients with colorectal cancer</article-title>. <source>Cancer Prev Res (Phila)</source>. <year>2015</year>;<volume>8</volume>(<issue>12</issue>):<fpage>1138</fpage>–<lpage>1145</lpage>.<pub-id pub-id-type="pmid">26382604</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Volkova</surname><given-names>E</given-names></string-name>, <string-name><surname>Willis</surname><given-names>JA</given-names></string-name>, <string-name><surname>Wells</surname><given-names>JE</given-names></string-name></person-group>, <etal>et al</etal><article-title>Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer</article-title>. <source>Br J Cancer</source>. <year>2011</year>;<volume>104</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>59</lpage>.<pub-id pub-id-type="pmid">21081932</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vaidya</surname><given-names>A</given-names></string-name>, <string-name><surname>Williams</surname><given-names>JS</given-names></string-name>, <string-name><surname>Forman</surname><given-names>JP.</given-names></string-name></person-group><article-title>The independent association between 25-hydroxyvitamin D and adiponectin and its relation with BMI in two large cohorts: the NHS and the HPFS</article-title>. <source>Obesity (Silver Spring).</source><year>2012</year>;<volume>20</volume>(<issue>1</issue>):<fpage>186</fpage>–<lpage>191</lpage>.<pub-id pub-id-type="pmid">21760630</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Holick</surname><given-names>MF.</given-names></string-name></person-group><article-title>Vitamin D deficiency</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>357</volume>(<issue>3</issue>):<fpage>266</fpage>–<lpage>281</lpage>.<pub-id pub-id-type="pmid">17634462</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gorham</surname><given-names>ED</given-names></string-name>, <string-name><surname>Garland</surname><given-names>CF</given-names></string-name>, <string-name><surname>Garland</surname><given-names>FC</given-names></string-name></person-group>, <etal>et al</etal><article-title>Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis</article-title>. <source>Am J Prev Med</source>. <year>2007</year>;<volume>32</volume>(<issue>3</issue>):<fpage>210</fpage>–<lpage>216</lpage>.<pub-id pub-id-type="pmid">17296473</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ng</surname><given-names>K</given-names></string-name>, <string-name><surname>Wolpin</surname><given-names>BM</given-names></string-name>, <string-name><surname>Meyerhardt</surname><given-names>JA</given-names></string-name></person-group>, <etal>et al</etal><article-title>Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer</article-title>. <source>Br J Cancer</source>. <year>2009</year>;<volume>101</volume>(<issue>6</issue>):<fpage>916</fpage>–<lpage>923</lpage>.<pub-id pub-id-type="pmid">19690551</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maalmi</surname><given-names>H</given-names></string-name>, <string-name><surname>Walter</surname><given-names>V</given-names></string-name>, <string-name><surname>Jansen</surname><given-names>L</given-names></string-name></person-group>, <etal>et al</etal><article-title>Association between blood 25-hydroxyvitamin D levels and survival in colorectal cancer patients: an updated systematic review and meta-analysis</article-title>. <source>Nutrients</source>. <year>2018</year>;<volume>10</volume>(<issue>7</issue>):896.</mixed-citation>
              </ref>
              <ref id="pkab070-B16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fuchs</surname><given-names>MA</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>C</given-names></string-name>, <string-name><surname>Sato</surname><given-names>K</given-names></string-name></person-group>, <etal>et al</etal><article-title>Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance)</article-title>. <source>Ann Oncol</source>. <year>2017</year>;<volume>28</volume>(<issue>6</issue>):<fpage>1359</fpage>–<lpage>1367</lpage>.<pub-id pub-id-type="pmid">28327908</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wesselink</surname><given-names>E</given-names></string-name>, <string-name><surname>Balvers</surname><given-names>M</given-names></string-name>, <string-name><surname>Bours</surname><given-names>MJL</given-names></string-name></person-group>, <etal>et al</etal><article-title>The association between circulating levels of vitamin D and inflammatory markers in the first 2 years after colorectal cancer diagnosis</article-title>. <source>Therap Adv Gastroenterol</source>. <year>2020</year>;<volume>13</volume>:<fpage>1756284820923922</fpage>.</mixed-citation>
              </ref>
              <ref id="pkab070-B18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname><given-names>M</given-names></string-name>, <string-name><surname>Nishihara</surname><given-names>R</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M</given-names></string-name></person-group>, <etal>et al</etal><article-title>Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status</article-title>. <source>Gut</source>. <year>2016</year>;<volume>65</volume>(<issue>2</issue>):<fpage>296</fpage>–<lpage>304</lpage>.<pub-id pub-id-type="pmid">25591978</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hamada</surname><given-names>T</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Nowak</surname><given-names>JA</given-names></string-name></person-group>, <etal>et al</etal><article-title>Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour</article-title>. <source>Eur J Cancer</source>. <year>2018</year>;<volume>103</volume>:<fpage>98</fpage>–<lpage>107</lpage>.<pub-id pub-id-type="pmid">30219720</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rozek</surname><given-names>LS</given-names></string-name>, <string-name><surname>Schmit</surname><given-names>SL</given-names></string-name>, <string-name><surname>Greenson</surname><given-names>JK</given-names></string-name></person-group>, <etal>et al</etal><article-title>Tumor-infiltrating lymphocytes, Crohn’s-like lymphoid reaction, and survival from colorectal cancer</article-title>. <source>J Natl Cancer Inst</source>. <year>2016</year>;<volume>108</volume>(8):djw027.</mixed-citation>
              </ref>
              <ref id="pkab070-B21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pages</surname><given-names>F</given-names></string-name>, <string-name><surname>Mlecnik</surname><given-names>B</given-names></string-name>, <string-name><surname>Marliot</surname><given-names>F</given-names></string-name></person-group>, <etal>et al</etal><article-title>International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study</article-title>. <source>Lancet</source>. <year>2018</year>;<volume>391</volume>(<issue>10135</issue>):<fpage>2128</fpage>–<lpage>2139</lpage>.<pub-id pub-id-type="pmid">29754777</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sinicrope</surname><given-names>FA</given-names></string-name>, <string-name><surname>Shi</surname><given-names>Q</given-names></string-name>, <string-name><surname>Hermitte</surname><given-names>F</given-names></string-name></person-group>, <etal>et al</etal><article-title>Contribution of immunoscore and molecular features to survival prediction in stage III colon cancer</article-title>. <source>JNCI Cancer Spectr</source>. <year>2020</year>;<volume>4</volume>(<issue>3</issue>):<fpage>pkaa023</fpage>.<pub-id pub-id-type="pmid">32455336</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shin</surname><given-names>DW</given-names></string-name>, <string-name><surname>Kim</surname><given-names>MA</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J-C</given-names></string-name></person-group>, <etal>et al</etal><article-title>Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial</article-title>. <source>BMC Res Notes</source>. <year>2021</year>;<volume>14</volume>(<issue>1</issue>):<fpage>272</fpage>–<lpage>1393</lpage>.<pub-id pub-id-type="pmid">34266478</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hollis</surname><given-names>BW.</given-names></string-name></person-group><article-title>Quantitation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D by radioimmunoassay using radioiodinated tracers</article-title>. <source>Methods Enzymol</source>. <year>1997</year>;<volume>282</volume>:<fpage>174</fpage>–<lpage>186</lpage>.<pub-id pub-id-type="pmid">9330287</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>H</given-names></string-name>, <string-name><surname>Sha</surname><given-names>D</given-names></string-name>, <string-name><surname>Foster</surname><given-names>NR</given-names></string-name></person-group>, <etal>et al</etal><article-title>Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance)</article-title>. <source>Ann Oncol</source>. <year>2020</year>;<volume>31</volume>(<issue>4</issue>):<fpage>487</fpage>–<lpage>494</lpage>.<pub-id pub-id-type="pmid">32165096</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yoon</surname><given-names>HH</given-names></string-name>, <string-name><surname>Tougeron</surname><given-names>D</given-names></string-name>, <string-name><surname>Shi</surname><given-names>Q</given-names></string-name></person-group>, <etal>et al</etal>; <collab>for the Alliance for Clinical Trials in Oncology</collab>. <article-title>KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance)</article-title>. <source>Clin Cancer Res</source>. <year>2014</year>;<volume>20</volume>(<issue>11</issue>):<fpage>3033</fpage>–<lpage>3043</lpage>.<pub-id pub-id-type="pmid">24687927</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saxena</surname><given-names>A</given-names></string-name>, <string-name><surname>Chumanevich</surname><given-names>A</given-names></string-name>, <string-name><surname>Fletcher</surname><given-names>E</given-names></string-name></person-group>, <etal>et al</etal><article-title>Adiponectin deficiency: role in chronic inflammation induced colon cancer</article-title>. <source>Biochim Biophys Acta</source>. <year>2012</year>;<volume>1822</volume>(<issue>4</issue>):<fpage>527</fpage>–<lpage>536</lpage>.<pub-id pub-id-type="pmid">22198319</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fenton</surname><given-names>JI</given-names></string-name>, <string-name><surname>Birmingham</surname><given-names>JM.</given-names></string-name></person-group><article-title>Adipokine regulation of colon cancer: adiponectin attenuates interleukin-6-induced colon carcinoma cell proliferation via STAT-3</article-title>. <source>Mol Carcinog</source>. <year>2010</year>;<volume>49</volume>(<issue>7</issue>):<fpage>700</fpage>–<lpage>709</lpage>.<pub-id pub-id-type="pmid">20564347</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yehuda-Shnaidman</surname><given-names>E</given-names></string-name>, <string-name><surname>Schwartz</surname><given-names>B.</given-names></string-name></person-group><article-title>Mechanisms linking obesity, inflammation and altered metabolism to colon carcinogenesis</article-title>. <source>Obes Rev</source>. <year>2012</year>;<volume>13</volume>(<issue>12</issue>):<fpage>1083</fpage>–<lpage>1095</lpage>.<pub-id pub-id-type="pmid">22937964</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arita</surname><given-names>Y</given-names></string-name>, <string-name><surname>Kihara</surname><given-names>S</given-names></string-name>, <string-name><surname>Ouchi</surname><given-names>N</given-names></string-name></person-group>, <etal>et al</etal><article-title>Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity</article-title>. <source>Biochem Biophys Res Commun</source> . <year>1999</year>;<volume>257</volume>(<issue>1</issue>):<fpage>79</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">10092513</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pais</surname><given-names>R</given-names></string-name>, <string-name><surname>Silaghi</surname><given-names>H</given-names></string-name>, <string-name><surname>Silaghi</surname><given-names>AC</given-names></string-name></person-group>, <etal>et al</etal><article-title>Metabolic syndrome and risk of subsequent colorectal cancer</article-title>. <source>World J Gastroenterol</source>. <year>2009</year>;<volume>15</volume>(<issue>41</issue>):<fpage>5141</fpage>–<lpage>5148</lpage>.<pub-id pub-id-type="pmid">19891012</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Makki</surname><given-names>K</given-names></string-name>, <string-name><surname>Froguel</surname><given-names>P</given-names></string-name>, <string-name><surname>Wolowczuk</surname><given-names>I.</given-names></string-name></person-group><article-title>Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines</article-title>. <source>ISRN Inflamm</source>. <year>2013</year>;<volume>2013</volume>:<fpage>139239</fpage>.<pub-id pub-id-type="pmid">24455420</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hivert</surname><given-names>MF</given-names></string-name>, <string-name><surname>Manning</surname><given-names>AK</given-names></string-name>, <string-name><surname>McAteer</surname><given-names>JB</given-names></string-name></person-group>, <etal>et al</etal><article-title>Common variants in the adiponectin gene (ADIPOQ) associated with plasma adiponectin levels, type 2 diabetes, and diabetes-related quantitative traits: the Framingham Offspring Study</article-title>. <source>Diabetes</source>. <year>2008</year>;<volume>57</volume>(<issue>12</issue>):<fpage>3353</fpage>–<lpage>3359</lpage>.<pub-id pub-id-type="pmid">18776141</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Böttner</surname><given-names>A</given-names></string-name>, <string-name><surname>Kratzsch</surname><given-names>JRGEN</given-names></string-name>, <string-name><surname>MüLler</surname><given-names>G</given-names></string-name></person-group>, <etal>et al</etal><article-title>Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2004</year>;<volume>89</volume>(<issue>8</issue>):<fpage>4053</fpage>–<lpage>4061</lpage>.<pub-id pub-id-type="pmid">15292348</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lanfranco</surname><given-names>F</given-names></string-name>, <string-name><surname>Zitzmann</surname><given-names>M</given-names></string-name>, <string-name><surname>Simoni</surname><given-names>M</given-names></string-name>, <string-name><surname>Nieschlag</surname><given-names>E.</given-names></string-name></person-group><article-title>Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy</article-title>. <source>Clin Endocrinol</source>. <year>2004</year>;<volume>60</volume>(<issue>4</issue>):<fpage>500</fpage>–<lpage>507</lpage>.</mixed-citation>
              </ref>
              <ref id="pkab070-B36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jürimäe</surname><given-names>J</given-names></string-name>, <string-name><surname>Jürimäe</surname><given-names>T.</given-names></string-name></person-group><article-title>Plasma adiponectin concentration in healthy pre- and postmenopausal women: relationship with body composition, bone mineral, and metabolic variables</article-title>. <source>Am J Physiol Endocrinol Metab</source>. <year>2007</year>;<volume>293</volume>(<issue>1</issue>):<fpage>E42</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">17341545</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gardener</surname><given-names>H</given-names></string-name>, <string-name><surname>Crisby</surname><given-names>M</given-names></string-name>, <string-name><surname>Sjoberg</surname><given-names>C</given-names></string-name></person-group>, <etal>et al</etal><article-title>Serum adiponectin in relation to race-ethnicity and vascular risk factors in the Northern Manhattan Study</article-title>. <source>Metab Syndr Relat Disord</source>. <year>2013</year>;<volume>11</volume>(<issue>1</issue>):<fpage>46</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">23127161</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cohen</surname><given-names>SS</given-names></string-name>, <string-name><surname>Gammon</surname><given-names>MD</given-names></string-name>, <string-name><surname>Signorello</surname><given-names>LB</given-names></string-name></person-group>, <etal>et al</etal><article-title>Serum adiponectin in relation to body mass index and other correlates in Black and White women</article-title>. <source>Ann Epidemiol</source>. <year>2011</year>;<volume>21</volume>(<issue>2</issue>):<fpage>86</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">21109453</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Looker</surname><given-names>AC</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>CL</given-names></string-name>, <string-name><surname>Lacher</surname><given-names>DA</given-names></string-name></person-group>, <etal>et al</etal><article-title>Vitamin D status: United States</article-title>. <source>NCHS Data Brief 2011</source>. <year>2011</year>;(<issue>59</issue>):<fpage>1</fpage>–<lpage>8</lpage>.</mixed-citation>
              </ref>
              <ref id="pkab070-B40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nesby-O’Dell</surname><given-names>S</given-names></string-name>, <string-name><surname>Scanlon</surname><given-names>KS</given-names></string-name>, <string-name><surname>Cogswell</surname><given-names>ME</given-names></string-name></person-group>, <etal>et al</etal><article-title>Hypovitaminosis D prevalence and determinants among African American and White women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994</article-title>. <source>Am J Clin Nutr</source>. <year>2002</year>;<volume>76</volume>(<issue>1</issue>):<fpage>187</fpage>–<lpage>192</lpage>.<pub-id pub-id-type="pmid">12081833</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Powe</surname><given-names>CE</given-names></string-name>, <string-name><surname>Evans</surname><given-names>MK</given-names></string-name>, <string-name><surname>Wenger</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal><article-title>Vitamin D-binding protein and vitamin D status of Black Americans and White Americans</article-title>. <source>N Engl J Med</source>. <year>2013</year>;<volume>369</volume>(<issue>21</issue>):<fpage>1991</fpage>–<lpage>2000</lpage>.<pub-id pub-id-type="pmid">24256378</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Verdoia</surname><given-names>M</given-names></string-name>, <string-name><surname>Schaffer</surname><given-names>A</given-names></string-name>, <string-name><surname>Barbieri</surname><given-names>L</given-names></string-name></person-group>, <etal>et al</etal><article-title>Impact of gender difference on vitamin D status and its relationship with the extent of coronary artery disease</article-title>. <source>Nutr Metabol Cardiovasc Dis</source>. <year>2015</year>;<volume>25</volume>(<issue>5</issue>):<fpage>464</fpage>–<lpage>470</lpage>.</mixed-citation>
              </ref>
              <ref id="pkab070-B43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lindberg</surname><given-names>S</given-names></string-name>, <string-name><surname>Jensen</surname><given-names>JS</given-names></string-name>, <string-name><surname>Pedersen</surname><given-names>SH</given-names></string-name></person-group>, <etal>et al</etal><article-title>Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction</article-title>. <source>Dia Care</source>. <year>2014</year>;<volume>37</volume>(<issue>11</issue>):<fpage>3003</fpage>–<lpage>3008</lpage>.</mixed-citation>
              </ref>
              <ref id="pkab070-B44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moon</surname><given-names>HS</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name><surname>Nagel</surname><given-names>JM</given-names></string-name></person-group>, <etal>et al</etal><article-title>Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice</article-title>. <source>Gut</source>. <year>2013</year>;<volume>62</volume>(<issue>4</issue>):<fpage>561</fpage>–<lpage>570</lpage>.<pub-id pub-id-type="pmid">22735569</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B45">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zgaga</surname><given-names>L</given-names></string-name>, <string-name><surname>Theodoratou</surname><given-names>E</given-names></string-name>, <string-name><surname>Farrington</surname><given-names>SM</given-names></string-name></person-group>, <etal>et al</etal><article-title>Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer</article-title>. <source>J Clin Oncol</source>. <year>2014</year>;<volume>32</volume>(<issue>23</issue>):<fpage>2430</fpage>–<lpage>2439</lpage>.<pub-id pub-id-type="pmid">25002714</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ng</surname><given-names>K</given-names></string-name>, <string-name><surname>Sargent</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Goldberg</surname><given-names>RM</given-names></string-name></person-group>, <etal>et al</etal><article-title>Vitamin D status in patients with stage IV colorectal cancer: findings from intergroup trial N9741</article-title>. <source>J Clin Oncol</source>. <year>2011</year>;<volume>29</volume>(<issue>12</issue>):<fpage>1599</fpage>–<lpage>1606</lpage>.<pub-id pub-id-type="pmid">21422438</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B47">
                <label>47</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ulrich</surname><given-names>CM</given-names></string-name>, <string-name><surname>Holmes</surname><given-names>RS.</given-names></string-name></person-group><article-title>Shedding light on colorectal cancer prognosis: vitamin D and beyond</article-title>. <source>J Clin Oncol</source>. <year>2008</year>;<volume>26</volume>(<issue>18</issue>):<fpage>2937</fpage>–<lpage>2939</lpage>.<pub-id pub-id-type="pmid">18565879</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B48">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hofmann</surname><given-names>JN</given-names></string-name>, <string-name><surname>Yu</surname><given-names>K</given-names></string-name>, <string-name><surname>Horst</surname><given-names>RL</given-names></string-name></person-group>, <etal>et al</etal><article-title>Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2010</year>;<volume>19</volume>(<issue>4</issue>):<fpage>927</fpage>–<lpage>931</lpage>.<pub-id pub-id-type="pmid">20332255</pub-id></mixed-citation>
              </ref>
              <ref id="pkab070-B49">
                <label>49</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>K</given-names></string-name>, <string-name><surname>Feskanich</surname><given-names>D</given-names></string-name>, <string-name><surname>Fuchs</surname><given-names>CS</given-names></string-name></person-group>, <etal>et al</etal><article-title>Interactions between plasma levels of 25-hydroxyvitamin D, insulin-like growth factor (IGF)-1 and C-peptide with risk of colorectal cancer</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>(<issue>12</issue>):<fpage>e28520</fpage>.<pub-id pub-id-type="pmid">22216097</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
